TABLE 1.
Demographic, clinical characteristics, and treatment patterns for patients with BRAF‐mutant advanced melanoma
| Overall (n = 224) | aPD‐1 (n = 81) | BRAF/MEKi (n = 143) | |
|---|---|---|---|
| Median age at 1L initiation, years (range) | 61 (26, 90+) | 62 (26, 90+) | 61 (28, 90+) |
| Race, n (%) | |||
| White | 201 (89.7) | 69 (85.2) | 132 (92.3) |
| Unknown | 18 (8.0) | 7 (8.6) | 11 (7.7) |
| Other | 5 (2.2) | 5 (6.2) | 0 (0.0) |
| Male sex, n (%) | 141 (62.9) | 50 (61.7) | 91 (63.6) |
| Median follow‐up time from 1L initiation, months (range) | 11.5 (0.2, 58.2) | 11.3 (0.4, 41.9) | 11.5 (0.2, 58.2) |
| ECOG performance status at 1L initiation, n (%) | |||
| 0‐1 | 142 (63.4) | 61 (75.3) | 81 (56.6) |
| 2+ | 35 (15.6) | 4 (4.9) | 31 (21.7) |
| Not documented | 47 (21.0) | 16 (19.8) | 31 (21.7) |
| Stage at diagnosis, n (%) | |||
| Stage I/II | 21 (9.4) | 6 (7.4) | 15 (10.5) |
| Stage III/IV | 167 (74.6) | 51 (63.0) | 116 (81.1) |
| Not documented | 36 (16.1) | 24 (29.6) | 12 (8.4) |
| PD‐L1 status, n (%) | |||
| Positive | 9 (4.0) | 6 (7.4) | 3 (2.1) |
| Negative | 16 (7.1) | 9 (11.1) | 7 (4.9) |
| Not documented | 199 (88.8) | 66 (81.5) | 133 (93.0) |
| LDH status at 1L initiation a , n (%) | |||
| Normal | 93 (41.5) | 41 (50.6) | 52 (36.4) |
| Elevated | 53 (23.7) | 15 (18.5) | 38 (26.6) |
| Not documented | 78 (34.8) | 25 (30.9) | 53 (37.1) |
| Sites of metastases at 1L initiation, n (%) | |||
| Other | 150 (67.0) | 45 (55.6) | 105 (73.4) |
| Lung | 101 (45.1) | 23 (28.4) | 78 (54.5) |
| Brain | 70 (31.3) | 17 (21.0) | 53 (37.1) |
| Bone | 59 (26.3) | 17 (21.0) | 42 (29.4) |
| Liver | 51 (22.8) | 7 (8.6) | 44 (30.8) |
| Metastatic status at 1L initiation, n (%) | |||
| M0 | 1 (0.4) | 0 (0.0) | 1 (0.7) |
| M1a | 19 (8.5) | 9 (11.1) | 10 (7.0) |
| M1b | 26 (11.6) | 9 (11.1) | 17 (11.9) |
| M1c | 145 (64.7) | 44 (54.3) | 101 (70.6) |
| Mx | 33 (14.7) | 19 (23.5) | 14 (9.8) |
| Median time from advanced melanoma diagnosis to 1L initiation, months (range) | 1.1 (0.0, 43.2) | 1.4 (0.0, 43.2) | 1.0 (0.0, 27.1) |
| Median duration of 1L therapy, months (range) | 5.0 (0.0, 57.4) | 3.7 (0.0, 41.9) | 5.4 (0.0, 57.4) |
| 1L regimen, n (%) | |||
| Dabrafenib/trametinib | 129 (57.6) | 0 (0.0) | 129 (90.2) |
| Pembrolizumab | 55 (24.6) | 55 (67.9) | 0 (0.0) |
| Nivolumab | 26 (11.6) | 26 (32.1) | 0 (0.0) |
| Cobimetinib/vemurafenib | 14 (6.3) | 0 (0.0) | 14 (9.8) |
| Radiation prior to 1L initiation, n (%) | 85 (37.9) | 30 (37.0) | 55 (38.5) |
| Prior radiation and brain metastases at 1L initiation, n (%) | 48 (21.4) | 13 (16.0) | 35 (24.5) |
| Surgical resection prior to 1L initiation, n (%) | 155 (69.2) | 61 (75.3) | 94 (65.7) |
| Patients who discontinued 1L treatment, n (%) | 196 (87.5) | 62 (76.5) | 134 (93.7) |
| Reasons for 1L treatment discontinuation, n (%) | |||
| Disease progression | 79 (40.3) | 28 (45.2) | 51 (38.1) |
| Other | 29 (14.8) | 10 (16.1) | 19 (14.2) |
| Treatment‐related toxicities | 26 (13.3) | 7 (11.3) | 19 (14.2) |
| Death | 16 (8.2) | 2 (3.2) | 14 (10.4) |
| Patient choice | 6 (3.1) | 4 (6.5) | 2 (1.5) |
| Decline in ECOG | 6 (3.1) | 1 (1.6) | 5 (3.7) |
| Unknown | 54 (27.6) | 14 (22.6) | 40 (29.9) |
| Patients who advanced to 2L, n (%) | 119 (53.1) | 35 (43.2) | 84 (58.7) |
| Median duration of 2L therapy, months (range) | 2.1 (0.0, 34.6) | 2.8 (0.0, 34.6) | 2.1 (0.0, 25.1) |
| 2L regimen, n (% of 2L initiators) | |||
| Pembrolizumab | 31 (26.1) | 2 (5.7) | 29 (34.5) |
| Nivolumab/ipilimumab | 26 (21.8) | 3 (8.6) | 23 (27.4) |
| Dabrafenib/trametinib | 20 (16.8) | 20 (57.1) | 0 (0.0) |
| Nivolumab | 16 (13.4) | 0 (0.0) | 16 (19.0) |
| Ipilimumab | 9 (7.6) | 3 (8.6) | 6 (7.1) |
| Other b | 17 (14.3) | 7 (20.0) | 10 (11.9) |
| Reasons for 2L treatment initiation, n (% of 2L initiators) | |||
| Progression on prior therapy | 80 (67.2) | 26 (74.3) | 54 (64.3) |
| Other | 16 (13.4) | 5 (14.3) | 11 (13.1) |
| Toxicity on prior therapy | 10 (8.4) | 4 (11.4) | 6 (7.1) |
| Unknown | 15 (12.6) | 1 (2.9) | 14 (16.7) |
| Patients who discontinued 2L treatment, n (% of 2L initiators) | 100 (84.0) | 26 (74.3) | 74 (88.1) |
| Reasons for 2L treatment discontinuation, n (% of 2L discontinuations) | |||
| Disease progression | 21 (21.0) | 4 (15.4) | 17 (23.0) |
| Treatment‐related toxicities | 14 (14.0) | 8 (30.8) | 6 (8.1) |
| Patients who advanced to 3L, n (% of 2L discontinuations) | 40 (17.9) | 5 (6.2) | 35 (24.5) |
Abbreviations: 1L, first‐line; 2L, second‐line; 3L, third‐line; aPD‐1, anti‐PD‐1 monotherapies; BRAF/MEKi, BRAF/MEK inhibitors; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; PD‐L1, programmed death ligand‐1.
a
LDH thresholds were recorded in the EHR based on individual laboratory specifications; standard reference ranges were not used.
b
Other 2L treatments were received by fewer than five patients in each cohort.